Anti-SEMA7A for the treatment of post-ischemic tissue damage
Anti-SEMA7A for the treatment of post-ischemic tissue damage
-
Anti-SEMA7A for the treatment of post-ischemic tissue damage
-
Hydrogel prevents post-infarct cardiac arrhythmia
Hydrogel prevents post-infarct cardiac arrhythmia
- Injectable hydrogel integrates and matures stem cell-derived cardiomyocytes safely
- Reduces risk of post-infarct arrhythmias
- Validated in in vivo studies
-
TMEM16A inhibitors as a treatment option for cystic fibrosis
TMEM16A inhibitors as a treatment option for cystic fibrosis
- TMEM16A inhibitors represent a causal treatment for cystic fibrosis
- They reduce both excessive mucus formation and airway contraction
- Repurposing possible: TMEM16A inhibitors include FDA-approved and well-tolerated drugs
3 of 97 Tech Offers
